Vincristine News and Research

RSS
Vincristine is the active ingredient in a drug used to treat acute leukemia. It is used in combination with other drugs to treat Hodgkin disease, non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms tumor. Vincristine is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division. It is a type of vinca alkaloid and a type of antimitotic agent.
Study finds no clear benefit of stem-cell transplant for double-hit lymphoma patients in remission

Study finds no clear benefit of stem-cell transplant for double-hit lymphoma patients in remission

Feinstein Institute research may lead to new treatment option for low-grade gliomas

Feinstein Institute research may lead to new treatment option for low-grade gliomas

New research reveals surprising culprit involved in self-destruction of axons

New research reveals surprising culprit involved in self-destruction of axons

Scientists discover genomic alterations in pediatric relapsed ALL

Scientists discover genomic alterations in pediatric relapsed ALL

Researchers identify higher risk of early chemotherapy-related death in older patients with DLBCL

Researchers identify higher risk of early chemotherapy-related death in older patients with DLBCL

Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

Radiation plus chemotherapy improves survival of low-grade brain cancer patients

Radiation plus chemotherapy improves survival of low-grade brain cancer patients

Radiation therapy plus PCV chemotherapy improves survival of low-grade glioma patients

Radiation therapy plus PCV chemotherapy improves survival of low-grade glioma patients

Abnormal breakage of chromosomes in white blood cells triggers aggressive form of ALL

Abnormal breakage of chromosomes in white blood cells triggers aggressive form of ALL

Positive bosutinib response for elderly blast phase CML patient

Positive bosutinib response for elderly blast phase CML patient

CASI Pharmaceuticals receives $10.3 million in strategic financing

CASI Pharmaceuticals receives $10.3 million in strategic financing

Scientists uncover novel strategy to block cancer's spread, restore tumor vulnerability to chemotherapy

Scientists uncover novel strategy to block cancer's spread, restore tumor vulnerability to chemotherapy

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Marqibo now available to leukemia patients through myTomorrows' Internet-based platform

Marqibo now available to leukemia patients through myTomorrows' Internet-based platform

Phase 1 BelCHOP study shows belinostat and CHOP chemo regimen as first-line treatment for PTCL

Phase 1 BelCHOP study shows belinostat and CHOP chemo regimen as first-line treatment for PTCL

CASI reports net loss of $1.6 million for third quarter 2015

CASI reports net loss of $1.6 million for third quarter 2015

Researchers pinpoint mechanisms that cause chemoresistance in ovarian cancer patients

Researchers pinpoint mechanisms that cause chemoresistance in ovarian cancer patients

CASI reports financial results for second quarter 2015

CASI reports financial results for second quarter 2015

Rare BCR-ABL fusions highlighted in CML

Rare BCR-ABL fusions highlighted in CML

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong